Kamada (KMDA) Net Income towards Common Stockholders (2012 - 2026)
Kamada (KMDA) posted quarterly Net Income towards Common Stockholders of $6.6 million for Q1 2026, down 28.2% year-on-year from $9.3 million in Q1 2025, and up 12.6% on a QoQ basis from $5.9 million in Q4 2025.
Kamada (KMDA) Net Income towards Common Stockholders (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Net Income towards Common Stockholders for 15 consecutive years, with $6.6 million the latest figure, recorded in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 28.2% year-over-year to $6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.0 million (up 38.82% YoY) and the FY2025 annual result came in at $26.7 million, up 119.04% from the prior year.
- Net Income towards Common Stockholders improved to $6.6 million in Q1 2026 per KMDA's latest filing, from $5.9 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for KMDA reached as high as $9.3 million in Q1 2025 and fell as low as -$1809.0 in Q1 2023.
- A 5-year average of $3.3 million and a median of $3.2 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The largest YoY upside for Net Income towards Common Stockholders was 537066.67% in 2023 against a maximum downside of 100.1% in 2023.
- Year by year, Net Income towards Common Stockholders stood at $3.2 million in 2022, then surged by 53.68% to $5.0 million in 2023, then slumped by 77.76% to $1.1 million in 2024, then surged by 432.07% to $5.9 million in 2025, then increased by 12.6% to $6.6 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $6.6 million, $5.9 million, and $7.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Kamada | 399.49 Mn | 326.34 Mn | 19.12 Mn | 6.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.65 Mn |
| Dec 31, 2025 | 5.91 Mn |
| Sep 30, 2025 | 7.44 Mn |
| Jun 30, 2025 | 6,328.00 |
| Mar 31, 2025 | 9.26 Mn |
| Dec 31, 2024 | 1.11 Mn |
| Sep 30, 2024 | 4.03 Mn |
| Jun 30, 2024 | 4,552.00 |
| Mar 31, 2024 | 2.51 Mn |
| Dec 31, 2023 | 4.99 Mn |
| Sep 30, 2023 | 3.22 Mn |
| Jun 30, 2023 | 1.81 Mn |
| Mar 31, 2023 | -1,809.00 |
| Dec 31, 2022 | 3.25 Mn |
| Sep 30, 2022 | 600.00 |
| Jun 30, 2022 | 3.95 Mn |
| Mar 31, 2022 | 1.83 Mn |
| Dec 31, 2021 | -4.82 Mn |
| Sep 30, 2021 | 868,000.00 |
| Jun 30, 2021 | 965,000.00 |